<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755638</url>
  </required_header>
  <id_info>
    <org_study_id>A031-01</org_study_id>
    <nct_id>NCT00755638</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ACE-031 (ActRIIB-IgG1) in Healthy, Postmenopausal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, randomized, single dose study to evaluate the safety, tolerability,&#xD;
      pharmacokinetic and pharmacodynamic effects of ACE-031 in healthy postmenopausal volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single, escalating doses of ACE-031 in healthy postmenopausal volunteers</measure>
    <time_frame>specified timepoints in the protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the pharmacokinetic (PK) and pharmacodynamic (PD) effects of ACE-031</measure>
    <time_frame>specified timepoints in the protocol</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects (6 active and 2 placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-031</intervention_name>
    <description>single subcutaneous dose of ACE-031</description>
    <arm_group_label>single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a postmenopausal woman, 45-75 years old (inclusive)&#xD;
&#xD;
          2. Subject has a body mass index (BMI) of &gt; 18.5 to &lt; 30&#xD;
&#xD;
          3. Subject must give written informed consent&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a history of malignancy. However, a subject with a history of excised or&#xD;
             treated basal cell carcinoma, cervical carcinoma in-situ, or less than or equal to 2&#xD;
             squamous cell carcinomas is eligible to participate in this study.&#xD;
&#xD;
          2. Subject has a history of clinically significant (as determined by the Investigator)&#xD;
             cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic,&#xD;
             pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease.&#xD;
&#xD;
          3. Subjects with chronic stable diseases including migraines, hypertension, hyperthyroid&#xD;
             disorder, hypothyroid disorder, gastroesophageal reflux disease, or mild&#xD;
             depression/anxiety will be excluded unless the investigator does not have safety or&#xD;
             compliance concerns at study entry.&#xD;
&#xD;
          4. Subject has a history of opportunistic infection (e.g. invasive candidiasis or&#xD;
             pneumocystis pneumonia).&#xD;
&#xD;
          5. Subject has had a serious local infection (e.g., cellulitis, abscess) or systemic&#xD;
             infection (e.g., septicemia) within the 3 months prior to screening.&#xD;
&#xD;
          6. Subject has a history of severe allergic or anaphylactic reactions.&#xD;
&#xD;
          7. Subject had surgery within the previous 3 months (other than minor cosmetic surgery or&#xD;
             minor dental procedures).&#xD;
&#xD;
          8. Subject had a fever (body temperature &gt; 38°C) or symptomatic viral or bacterial&#xD;
             infection within 2 weeks prior to dosing.&#xD;
&#xD;
          9. Subject has a positive Tuberculin skin test (Mantoux)&#xD;
&#xD;
         10. Subject has a history of hepatitis B surface antigen (HBsAg), hepatitis C antibody&#xD;
             (HCV), or human immunodeficiency virus (HIV).&#xD;
&#xD;
         11. Subject has a recent or clinically significant history of drug or alcohol abuse, or&#xD;
             tests positive in a urine screen for alcohol or drugs of abuse.&#xD;
&#xD;
         12. Subject consumed any alcohol within 48 hours prior to dosing.&#xD;
&#xD;
         13. Subject has donated or lost ≥ 499 mL of whole blood within 56 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
         14. Subject has taken any hormone replacement therapy within 3 months prior to study&#xD;
             enrollment, or plans to begin hormone replacement therapy at any time during the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>July 10, 2009</last_update_submitted>
  <last_update_submitted_qc>July 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Niels Borgstein, MD</name_title>
    <organization>Acceleron Pharma Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

